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In The Lancet Infectious Diseases, Robert Aldridge and 
colleagues1 report the results of a systematic review on 
pre-entry screening for tuberculosis. They conclude that 
it should be considered as part of a broad package of 
activities for tuberculosis care, prevention, and control 
in migrants.
Pre-entry screening refers to screening of people who 
intend to migrate—ie, before they leave their country 
of origin. Alternative strategies include upon-entry or 
post-entry screening. Because in many countries with 
a low incidence of tuberculosis a high proportion of 
the burden of tuberculosis is present in foreign-born 
people with tuberculosis,2 there is a lively debate on 
whether screening should be implemented and, if so, 
what approach should be used.3 A recent WHO guideline 
includes a conditional recommendation (based on 
very low-quality evidence) for systematic screening for 
active tuberculosis in subpopulations that have very 
high tuberculosis rates or very poor access to health 
care, such as some migrants and refugees residing in, 
or coming from, settings with a high prevalence of 
tuberculosis. The guideline stresses the need to prioritise 
only groups with very high risk.4 With the exception of 
some refugees, migrants are usually not a risk group in 
their country of origin, but might be deemed a high-risk 
group from the perspective of the receiving country.
Unsurprisingly, Aldridge and colleagues report that 
the yield of pre-entry screening for tuberculosis is 
strongly correlated with the tuberculosis incidence 
in the country of origin.1 This correlation is the same 
for post-entry screening.5 Countries use diﬀ erent 
tuberculosis incidence thresholds to deﬁ ne from which 
countries of origin migrants should be screened.6 Thus, 
the quantiﬁ cation of the yield in migrants from diﬀ erent 
countries of origin provided by Aldridge and colleagues 
is important to guide prioritisation of countries of origin 
to focus the screening.
Only a few low-incidence countries undertake pre-
entry tuberculosis screening.6 As Aldridge and colleagues 
report, the cost-eﬀ ectiveness of pre-entry screening, 
but also of post-entry screening, is unknown. More 
importantly, there are few data on the eﬀ ect of any 
type of migrant tuberculosis screening on tuberculosis 
epidemiology.7 Also, the claim that migrant screening 
is done to protect the health of the autochthonous 
population has not been substantiated by proof that 
there is substantial transmission from migrants to the 
native population that can be prevented by screening.8 
Even though evidence is weak, in view of the aim to 
eliminate tuberculosis as a public health problem, 
migrant screening in low-incidence countries might be 
considered after a careful epidemiological assessment, 
coupled with detailed monitoring and assessment.9
Pre-entry screening is conventionally ﬁ nanced out-
of-pocket by visa applicants, whereas treatment is paid 
either out-of-pocket, by health insurance, or by a national 
tuberculosis programme. Therefore, cost savings might 
be associated with pre-entry screening for the receiving 
country, by reduction of screening and treatment costs 
after arrival. Shifting costs to the country of origin 
could reduce overall cost from an international societal 
perspective because health care costs are normally much 
higher in the receiving country. However, ﬁ nancial burden, 
equity, and ethics need to be considered, including the risk 
of stigma and discrimination. The countries discussed in 
the report grant visas after completion of tuberculosis 
treatment. However, some other countries use pre-
entry screening to unconditionally refuse entry even if 
screen-positive individuals were to be treated before 
migration—a discriminatory approach without any 
epidemiological rationale.10,11
When doing pre-entry screening it is important to 
establish good collaboration and data sharing with 
the disease control agency in the country of origin. 
Setting up good laboratory facilities and ensuring high 
standards of tuberculosis diagnosis and treatment are 
essential, and can beneﬁ t the country of origin. It has 
also been shown that by helping to improve the overall 
tuberculosis control approaches in high-incidence 
countries from which many of their migrants originate, 
receiving countries can deliver cost savings.12
We agree with Aldridge and colleagues that pre-entry 
screening is only one potential element of a strategy to 
improve tuberculosis care and prevention for migrants. 
Full health care access post-migration is the ﬁ rst 
priority. Strategies need to cover the full continuum of 
tuberculosis prevention and care pre-migration and 
post-migration, including support to global tuberculosis 
control and addressing underlying determinants of 
tuberculosis.9
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 Interplay between childhood pneumonia and HIV infection
The old adage “If you want to go there, I wouldn’t 
start from here” applies to more than a few systematic 
reviews. However elegantly designed, systematic 
reviews are at the mercy of what the scientiﬁ c 
literature happens to contain on a chosen topic. For 
comorbidity studies in particular, investigators might 
have diﬃ  culty ﬁ nding content that systematically 
makes connections between conditions. In a 
systematic review and meta-analysis published in 
The Lancet Infectious Diseases, Evropi Theodoratou 
and colleagues1 try to assess the relation between 
childhood pneumonia and HIV infection, and then 
extrapolate to possible global burdens. Inevitably, 
the review mainly identiﬁ ed studies of hospital 
admissions, because unambiguous diagnosis of 
pneumonia and HIV infection is otherwise unlikely. 
Nevertheless, HIV-infected children had substantially 
increased risks of hospital admission for pneumonia 
(odds ratio [OR] 6·5, 95% CI 5·9–7·2) and of dying 
from pneumonia (5·9, 2·7–12·7).
Understanding the Article’s ﬁ ndings in relation 
to population health is diﬃ  cult because—especially 
in sub-Saharan Africa—HIV-infected children with 
pneumonia might not necessarily be admitted to 
hospital. A verbal autopsy dataset2,3 collected by the 
INDEPTH Network (based on interviewing family 
members following a death4) provides an opportunity 
to calculate population-based pneumonia and HIV/
AIDS-related cause-speciﬁ c mortality rates (including 
deaths in hospital). The dataset contains information 
for 19 731 deaths over 1·53 million person-years 
in children aged 1–59 months, across 18 sites in 
sub-Saharan Africa and southeast Asia. Pneumonia 
mortality rates ranged from 0·5 (FilaBavi, Vietnam) 
to 9·7 (Kisumu, Kenya) per 1000 person-years and 
HIV/AIDS-related mortality rates ranged from 0·01 
(Chakaria, Bangladesh) to 6·0 (Kisumu, Kenya) per 
1000 person-years. The correlation between the 
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Figure: Causes of death of children aged 1–59 months in a rural South African region
Causes of 1623 deaths determined by verbal autopsy among children aged 1–59 months at the INDEPTH 
Network member Agincourt Health and Demographic Surveillance Site in rural South Africa during a major HIV/
AIDS epidemic.2
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